Try our beta test site
46 studies found for:    "Li Fraumeni syndrome"
Show Display Options
Rank Status Study
21 Completed A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Condition: Ovarian Cancer
Interventions: Drug: MK-1775;   Drug: Placebo;   Drug: paclitaxel;   Drug: carboplatin
22 Terminated Wild Type p53 Adenovirus for Oral Premalignancies
Condition: Mouth Cancer
Intervention: Genetic: INGN 201
23 Completed Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: Ad5CMV-p53 gene;   Procedure: conventional surgery
24 Recruiting Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Procedure: Blood specimen
25 Completed Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease
Condition: Graves' Disease
Intervention:
26 Unknown  Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention: Biological: Ad5CMV-p53 gene
27 Recruiting Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Condition: GLIOBLASTOMA
Interventions: Genetic: SGT-53;   Drug: Temozolomide
28 Recruiting Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Interventions: Genetic: SGT-53;   Drug: nab-paclitaxel;   Drug: Gemcitabine
29 Recruiting p53 and Response to Preoperative Radiotherapy for T2 and T3
Condition: Rectal Cancer
Intervention: Radiation: preoperative short course radiation
30 Unknown  Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer
Condition: Breast Cancer
Interventions: Genetic: cytogenetic analysis;   Genetic: proteomic profiling;   Other: cytology specimen collection procedure;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: breast duct lavage
31 Recruiting ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Conditions: Solid Tumor;   Lymphoma;   Peripheral T-Cell Lymphoma
Intervention: Drug: ALRN-6924
32 Completed Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Biological: Autologous dendritic cell-adenovirus p53 vaccine;   Drug: Carboplatin;   Drug: Etoposide
33 Completed Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
Conditions: Lip and Oral Cavity Cancer;   Oropharyngeal Cancer;   Stage 0 Lip and Oral Cavity Cancer;   Stage 0 Oropharyngeal Cancer;   Tongue Cancer
Interventions: Biological: Ad5CMV-p53 gene;   Other: laboratory biomarker analysis
34 Active, not recruiting
Has Results
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
Condition: Small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Biological: Drug: Ad.p53-DC vaccines;   Drug: All -trans Retinoic Acid (ATRA)
35 Recruiting Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Conditions: Stomach Neoplasms;   Stomach Cancer;   Familial Cancer;   Fundic Gland Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   Peutz-Jeghers Syndrome
Intervention:
36 Recruiting Familial Investigations of Childhood Cancer Predisposition
Conditions: Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
Intervention:
37 Completed P53 in Differentiated Thyroid Cancer
Condition: Thyroid Neoplasms
Intervention:
38 Recruiting Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
Conditions: Adult Solid Neoplasm;   Bladder Carcinoma;   Colon Carcinoma;   Estrogen Receptor Negative;   Head and Neck Squamous Cell Carcinoma;   Hepatocellular Carcinoma;   HER2/Neu Negative;   Melanoma;   Non-Small Cell Lung Carcinoma;   Pancreatic Carcinoma;   Progesterone Receptor Negative;   Rectal Carcinoma;   Renal Cell Carcinoma;   Soft Tissue Sarcoma;   Triple-Negative Breast Carcinoma;   TP53 Gene Mutation;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Modified Vaccinia Virus Ankara Vaccine Expressing p53;   Biological: Pembrolizumab
39 Recruiting Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer
Condition: Colorectal Carcinoma
Intervention: Biological: re-activated T cells
40 Withdrawn Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
Condition: Acute Myelogenous Leukemia
Interventions: Drug: cenersen;   Drug: placebo;   Drug: idarubicin, cytarabine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-46) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.